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Summary: The detection of hepatitis C virus infection currently relies on a "virology without a virus"
approach. So far, only viral nucleic acid has been isolated and sequenced by the methods of genetic engineering.
The resulting viral sequence was then used to "design" proteins for diagnostic use as antigens in enzyme
immunoassays (EIA).
A first-generation EIA (EIA I), which uses a non-structural hepatitis C virus protein as antigen, detected 26
(0.6%) reactive sera out of a total of 4350 blood donors. An inhibition test using recombinant hepatitis C
virus antigen, and EIAs using other, both synthetic and recombinant hepatitis C virus peptides were used as
a specificity enhancing measure and as confirmatory tests, respectively. Only 7 of these reactives (0.16%,
inhibition test) and 5 (0.11%, peptide EIA) were confirmed positive. Of the 26 initially reactive donor sera,
5 sera (0.11%) reacted positive in a second-generation anti-hepatitis C virus antibody EIA (EIA II), which
uses two different recombinant non-structural hepatitis C virus proteins and one recombinant core protein.
Seventeen (77%) of 22 haemophiliacs reacted positive in EIA I, and 19 (86%) did so in EIA II. There were
no false positives in this cohort.
Twenty-eight (19%) out of 148 liver disease patients showed a positive reaction in EIA I, and 31 (21%) were
reactive in EIA II. Based on the results of the peptide enzyme immunoassay, 1 serum of this group was false
positive in EIA I, while none of the sera of this group were false positive in EIA II.
Parallel testing of 42 anti-hepatitis C virus-positive sera in geometric serial dilutions gave a median titre of
71.8 for the triple-antigen assay (EIA II) versus a median titre of only 17.4 for the single-antigen test (EIA I).
In four out of eight sera exclusively positive in EIA II, the presence of antibodies to epitopes not used in
EIA I was demonstrated by enzyme immunoassays with defined hepatitis C virus peptides.
In conclusion, the analytical sensitivity of EIA II is greater than that of EIA I. In conjunction with its better
specificity (improved positive predictive value), as clearly demonstrated in a low-prevalence cohort of blood
donors, the three antigen EIA (EIA II) offers considerable diagnostic progress.
J) Some of the results of this study were presented at the Annual Meeting of the Deutsche Gesellschaft für Klinische Chemie in
Nuremberg, Germany, in October, 1991.
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Introduction
Non-A, non-B hepatitis not only accounts for as many
as 80 — 90 percent of all cases of posttransfusion hep-
atitis but is indeed the most frequent of all infectious
complications of blood transfusions (for a review see
l.c.(l)).
The causative virus of most of these cases of hepatitis,
now called hepatitis C virus, was discovered as re-
cently as 1988 by molecular biology methods (2). Soon
afterwards, the same team developed a test that was
capable of detecting antibodies to a fusion protein of
human Superoxide dismutase and a viral gene product
(polypeptide C100-3, consisting of 527 amino acids)
(3). This protein, which is used for coating reactive
surfaces for enzyme immunoassays (EIAs), was ex-
pressed in yeast by genetic engineering methods.
Apart from the immunogenic moiety of hepatitis C
virus polypeptide C100 (363 amino acids), this fusion
protein also contains linker sequences and, for en-
hanced expression, 154 amino acids of human super-
oxide dismutase (3, 4). This test system (3) causes
positive reactions in about 80 percent of all patients
who acquired non-A,non-B hepatitis via blood or
blood products (3, 5 — 8). Haemophiliacs, who had
been high-risk patients for all infections transmissible
through blood products, are reactive for anti-hepatitis
C virus antibody in this enzyme immunoassay in 60 —
80 percent of cases (9, 10). The prevalence of anti-
hepatitis C virus antibody in blood donors is signifi-
cantly lower, typically less than 1 percent (11 — 13,
16).
Of central interest to transfusion medicine is the extent
to which reactivity in the EIA described above is
correlated with the infectiousness of reactive blood
donations.
The reverse transcriptase and polymerase chain re-
action combination detected viral nucleic acid in al-
most all specifically antibody positive donor sera (14).
Earlier investigations demonstrated that the percent-
age of initially C100-3 antibody-positive blood do-
nations that transmitted hepatitis C virus infections
to recipients (16, 17) was essentially identical with the
more recently determinable percentage of confirmed
EIA positive sera (14, 15, 30).
As the polymerase chain reaction is — at least for the
time being — not a feasible approach^ to blood donor
screening, improvement in the specificity and sensitiv-




We analysed sera from 4350 blood donors at the Herzzentrum
Nordrhein-Westfalen, Germany, whose donations had been
screened for hepatitis C virus antibodies. In addition, we used
sera from a cohort of 22 haemophiliacs (17 with haemophilia
A, 5 with haemophilia B), as well as 148 sera from patients
with liver disease. Nineteen of the haemophiliac patients had
been treated with non-virus inactivated plasma products before
1985. The sera from cases of liver disease originated from
patients for whom the treating physician had requested the
determination of the anti-hepatitis C virus antibody status for
evaluation of the cause of the liver disease.
First-generation, single antigen ant i -hepat i t i s C
virus enzyme immunoassay
The EIA was performed exactly as specified in the manufac-
turer's (Abbott, Wiesbaden, Germany) assay procedure. The
anti-hepatitis C virus EIA is based on the following principle:
C100-3 fusion protein isolated and purified from yeast cells is
bound to a reactive surface. In the first incubation step, anti-
body present in the 1 :40 diluted sample reacts with the solid
phase bound antigen. After a wash procedure, peroxidase-
conjugated anti-human IgG is added. The resulting "sandwich"
structure can be detected spectrophotometrically at 490 nm by
conversion of the substrate, o-phenylenediamine. For reading
results, a cutoff is calculated from the mean of the absorbances
of the negative controls plus 25% of the mean of the absorb-
ances of positive controls. Samples showing an absorbance
greater than the cutoff were considered EIA positive.
To obtain a measure of the antibody concentrations in the EIA-
positive samples, geometric serial dilutions of these samples
were prepared with pooled anti-hepatitis C virus-negative (in
EIA II) serum, thus enabling the determination of the greatest
above-cutoff dilution (titre).
Second-generation, triple recombinant antigen anti-
hepatit is C virus enzyme immunoassay
The assay procedure of the second-generation, three recombi-
nant antigen anti-hepatitis C virus enzyme immunoassay (EIA
II) (Abbott, Wiesbaden, Germany) is essentially identical with
that of the first-generation enzyme immunoassay (EIA I); for
details see above. The solid phase (bead surface) of EIA II is
coated with three distinct recombinant antigens, C100, 33c, and
the core antigen. To scavenge non-specifically reacting antibod-
ies, the sample diluent contains a lysate of E. coli and yeasts,
as well as soluble Superoxide dismutase.
Defined hepatitis C virus peptide antigen confir-
matory enzyme immunoassay
The assay procedure of this type of EIA is essentially identical
with that of EIA I (see above). Beads coated with peptides
sp65/67, sp75, and 33c are used as the solid phase. While sp75
is a core peptide, sp65/67 and 33c are derived from the non-
structural portion of the hepatitis C virus genome. Peptides
sp67/67 and sp75 are fully synthetic, while antigen 33c is re-
combinant (all from Abbott, Wiesbaden, Germany). Figure 1
shows the assignment of these peptides to the hepatitis C virus
genome. All sera reacting in the first-and/or second-generation
enzyme immunoassays were tested with peptide EIA.
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Fig. 1. Position in the hepatitis C virus genome and size of five hepatitis C virus peptides used in enzyme immunoassays (from
I.e. (31), modified).
NS 1 to NS 5: non-structural proteins
EIA 1st generation: C100
EIA 2nd generation: core, 33c, C100
Peptide EIA's: using either sp65/67, sp75 or 33c
Hepati t is C virus inhibi t ion test (neutral izat ion test) Statistical methods
A neutralization test using a soluble, highly purified recombi-
nant hepatitis C virus antigen (Abbott, Wiesbaden, Germany)
(a partial sequence of the clOO antigen) was used as a specificity
enhancing measure in all EIA-positive samples. This recombi-
nant hepatitis C virus antigen consists of 256 of the 363 amino
acids of hepatitis C virus protein ClOO (21). Sample antibodies
specifically directed against the hepatitis C virus antigen can
be neutralized by the soluble antigen via immune complex
formation, i.e. it is no longer available for sandwiching in a
subsequent EIA. As a result, the absorbance of specifically
neutralized samples is significantly lower than that of the con-
trol. Two aliquots (100 μΐ) of sample were each diluted 1 :40
with neutralization reagent and incubated at 40 °C for 30 min-
utes for further antibody neutralization. Another two aliquots
were diluted 1 : 40 in sample diluent (yeast extract plus bovine
serum and goat serum) and used as controls. After neutraliza-
tion, a ClOO antigen-coated bead of the EIA was added, and
the assay continued as for screening. A sample was considered
specifically neutralizable and hence positive if the absorbance
of the neutralized aliquots was less than 50 percent of the
absorbance of the controls. To demonstrate the inhibition effect,
geometric serial dilutions of the recombinant antigen solution
(initial concentration 160 mg/1) were prepared with sample
diluent. The inhibition solutions of different concentrations
were used to preincubate 5 specifically anti-hepatitis C virus
positive sera.
Determination of the detection limits of the one- and
three-antigen EIAs
The analytical sensitivity of the single- and triple-antigen EIAs
was determined in 42 sera that were positive in the inhibition
test, and which originated from liver disease patients, haemo-
philiacs, and blood donors. Pooled anti-hepatitis C virus-neg-
ative (EIA II) blood donor sera were used to prepare geometric
serial dilutions. The greatest dilution that still gave a positive
reaction was reported as the titre.
Other tests
The alanine aminotransferase was determined by the optimized
standard method of the Deutsche Gesellschaft f r Klinische
Chemie (assay temperature: 25 °C). The upper limit of the
reference range for blood donors in our laboratory is 25 U/l.
Given that the titres showed an approximately log-normal
distribution, we calculated the median and spread. The loga-
rithms of the titres were used for setting up the linear regression
curve. The signed rank test for non-parametric comparison of
paired samples was used to analyse the significance of the
differences between the detection limits of two enzyme immu-
noassays.
Results
Of the 4350 blood donors studied by us, 26 were
reactive in the first-generation enzyme immunoassay
(EIA I). In the group of 281 blood donors with
elevated alanine aminotransferase, one serum was po-
sitive in EIA I (tab. 1). All sera reacting positive in
EIA I were analysed by the inhibition test for en-
hanced specificity, including those from haemophi-
liacs and liver disease patients. In order to characterize
the inhibition test we retested five highly positive sera
in the EIA at various dilutions of the inhibition an-
tigen. This dilution experiment revealed that the in-
hibition antigen was present in more than 10-fold
excess (fig. 2).
All EIA I positive haemophiliacs (17/17) were positive
in the inhibition test, and all had been treated with
non-virus-inactivated plasma products in the pre
AIDS era. Twenty-three of the 28 (82%) liver disease
patients who were reactive in EIA I gave a positive
inhibition test. Only 27% (7/26) of the blood donors
were positive in the inhibition test (tab. 1). The dif-
ferences between the three cohorts are statistically
significant in the x2-test (p < 0.01). The triple-antigen
EIA II was used in a subcohort of n = 1000 blood
donors. Three reacted positively in EIA II and one
of these reactive sera did not show a positive reaction
in EIA I. In the same subcohort, 9 sera were reactive
in EIA I, only 2 of which were positive in the peptide
enzyme immunoassay and inhibition test.
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Fig. 2. Influence of various concentrations of the recombinant
inhibition antigen on the absorbance of the enzyme
immunoassay.
The curves of five specifically hepatitis C virus antibody
positive sera are shown.
The concentration of the inhibition antigen was 160
mg/l.
Nineteen of the 22 haemophiliac sera were reactive in
EIA II, including two sera that were not reactive in
EIA I. A similar trend emerged for the liver disease
patients: all but one of the 28 sera that reacted posi-
tively in the first-generation enzyme immunoassay
were also reactive in EIA II. The one serum positive
in EIA I but negative in EIA II gave a negative
inhibition test. Twenty-three out of 28 (82%) were
positive in the inhibition test. In addition, there were
3 sera that were reactive in EIA II only (tab. 1).
Of the 26 blood donors with a positive reaction in
EIA I, only 5 were reactive in EIA II (predictive value
of EIA I: 0.19 in tab. 1). The positive predictive value
of a reactive one-antigen EIA is therefore low. It can
be improved considerably by an additional inhibition
test (tab. 1).
Eight sera of all cohorts tested by us had a positive
EIA II, but gave a negative result in EIA I. These
inconsistently reacting sera, which suggest a greater
sensitivity of the EIA II, were retested by defined
short-chain hepatitis C virus peptide EIAs. Four of
these sera showed positive reactions with peptides
sp65/67, which are fragments of the C100 antigen (fig.
1 and tab. 2). Another two sera did not react in the
EIA with sp65/67 or sp75, but they did react with
non-C100-overlapping peptide 33c (fig. 1 and tab. 2).
Figure 3 compares the analytical sensitivities of the
enzyme immunoassays by parallel determinations of
the highest dilution in anti-hepatitis C virus negative
(EIA II) serum which still gives a positive reaction in
a given EIA. All but one out of the 42 tested sera
showed a higher titre in EIA II (fig. 3). The median
serum titre of the first-generation EIA was 17.4 versus
71.8 for the second-generation EIA.
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Tab. 2. Reactivity in peptide enzyme immunoassay s for confirmation of 8 sera which reacted positive in the second generation
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Fig. 3. Analytical sensitivity of anti-hepatitis C virus enzyme
immunoassay. The titres of 42 sera were simultaneously
determined in the first generation (one antigen) and the
second generation (triple antigen) enzyme immunoas-
say s (EIA's).
Titres:
EIA first generation (n = 42): 17.4 (median)
EIA second generation (n = 42): 71.8 (median)
of two anti-hepatitis C virus enzyme immunoassay s.
Ο — ο: First generation (one antigen) anti-hepatitis
C virus enzyme immunoassay
• ·: Second generation (triple antigen) anti-hep-
atitis C virus enzyme' immunoassay
Ax/Acut 0(T: ratio of absorbance of a particular serum
sample to the calculated absorbance of the
cut off value
Figure 4 illustrates the relationship between the ab-
sorbance of undiluted serum in the EIA at 490 nm
and the resulting titre of 42 samples that were reactive
in both EIAs. Tested by EIA I, most of the undiluted
samples showed an absorbance of greater than 2.0,
which corresponds to a titre of 1 :16 to 1 :1024. Low
titres show a moderate correlation with absorbance.
EIA Η-positive samples show a better absorbance-
titre correlation. Thus, figure 4 shows a clearly dif-
ferent A/A cutoff titre relationship for the subset of
reactive EIA II tests.
Discussion
Since the first report in 1989 (3) of an enzyme im-
munoassay that gives positive reactions in the major-
ity of patients with non-A, non-B hepatitis, this EIA
has been used widely all over the world. In Germany,
for instance, all blood banks perform an anti-hepatitis
C virus screening. Worldwide prevalences (for a re-
view see I.e. (4)) are reported to range between 0.4
and 1.4 percent, as determined by first-generation
enzyme immunoassay (EIA I, C100 antigen). The
objective of further investigations was to determine
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 7
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the percentage of EIA-reactive blood products that
had caused hepatitis in the recipient or tested positive
for hepatitis C virus nucleic acid by reverse transcrip-
tion and polymerase chain reaction. The percentage
of blood products affected in this way ranged from
15 to 25 percent (16,17,14). The resulting percentage
of infectious sera among hepatitis C virus antibody
positive sera appears quite small and is indeed con-
siderably larger, when the 70 percent false positives
of El A I (recombinant C100 antigen) in blood donors
(15, 14, 22) are excluded. Since there is a close cor-
relation between potential infectiousness, as demon-
strated by the polymerase chain reaction, and the
detection of anti-hypatitis C virus antibodies (14, 23),
and since the polymerase chain reaction is as yet not
suitable for routine screening, the development of a
sensitive and specific immunologic method for hepa-
titis C virus antibody detection is a prime diagnostic
concern.
We therefore analysed our cohort of 4350 blood do-
nors and obtained n = 26 (0.6%) reactive sera in EIA
I (recombinant C100 antigen). In 281 blood donor
sera with elevated alanine aminotransferase (> 25
U/l) there was one anti-hepatitis C virus positive
serum, showing that the prevalence is no higher in
this surrogate marker positive subgroup (tab. 1). Re-
testing of the 26 EIA I reactive sera by the second-
generation enzyme immunoassay (three distinct solid
phase bound hepatitis C virus antigens) yielded merely
5 reactive sera (81 percent false positives). The inhi-
bition test and peptide enzyme immunoassay gave
similiar results (tab. 1). It is important that all EIA
II positive sera were confirmed positive by peptide
enzyme immunoassay (tab. 1).
The percentage of false positives by EIA I is signifi-
cantly lower in groups of haemophiliacs, who are at
a much higher risk of hepatitis C virus infection, and
in liver disease patients (tab. 1). In a cohort of 22
haemophilia patients, 17 had confirmed hepatitis C
virus antibodies. All of the latter patients had been
treated with non-virus-inactivated plasma products in
the pre AIDS era. The positive predictive value of a
first-generation enzyme immunoassay (C100 antigen
only) is high (> 0.8) in groups at high risk of hepatitis
C infection. In blood donor, i. e. low risk populations,
on the other hand, the positive predictive value is as
low as 0.2-0.3 (tab. 1). Thus, particularly in this
group, a positive test result has to be interpreted with
great caution.
The positive predictive value of an anti-hepatitis C
virus antibody enzyme immunoassay for blood donor
screening was improved significantly by the use of
second-generation EIA, at the same time enhancing
the diagnostic sensitivity of the test. Thus, in a sub-
cohort of n = 1000 blood donors tested by us, we
obtained 9 reactive sera in EIA I and 3 reactive sera
in EIA II; one of the latter 3 had not been detected
by EIA I (data not shown). In the liver disease and
haemophiliac cohorts, there was also a small number
of sera that reacted positive in the second-generation
enzyme immunoassay only, thus indicating a greater
diagnostic sensitivity of this new EIA (tab. 1).
These EIA I false negatives were retested by addi-
tional enzyme immunoassays using defined short pro-
tein sequences of the hepatitis C virus polyprotein
(fig. 1). Four of these 8 sera showed positive reactions
with peptides sp65/67. These peptides are fragments
of the C100-3 antigen used in EIA I, which would
therefore have been expected to be reactive as well.
Failure of EIA I to give positive reactions in these 4
sera may be due to differences in the antigen concen-
trations used by the tests and/or to conformation-
related suboptimal accessibility of certain epitopes in
the native C100 antigen. The strong reactivity of these
4 sera in the second-generation enzyme immunoassay
can be accounted for by the use of a core antigen in
EIA II. Two sera (tab. 2) reacted neither with the
C100 antigen of the first-generation enzyme immu-
noassay, nor with C100 antigen fragments sp65/67,
nor with core peptide sp75. Exclusive reactivity of
these two sera in EIA II was demonstrated by a highly
positive reaction with the 33c clone, which is different
from the C100 antigen. The 33c antigen is used only
in the second-generation EIA and, like the C100 an-
tigen, is a non-structural protein. In three sera of the
hepathopathy group a positive result with EIA I, EIA
II and peptide EIA with sp65/57 was obtained, but
the inhibition test was negative (data not shown). The
negative results in the inhibition test in these cases
can only be explained by the presence of antibodies
to the 107 amino acid portion of the C100 antigen
which does not overlap the inhibition antigen.
Parallel determinations of the titres of 42 sera that
were reactive in both enzyme immunoassays showed
that all but one serum yielded higher titres in EIA II
(fig. 3). The average (median) titre of the 42 hepatitis
C virus positive sera was 17.4 for EIA I and 71.6 for
EIA II. As an anti-hepatitis C virus positive serum
contains a mixture of antibodies to different epitopes
of the hepatitis C virus polyprotein, the greater ana-
lytical sensitivity of EIA II is presumably the result
of its greater antibody solid phase binding capabilities.
Neither the absorbance value nor the absorbance/
absorbance of cut off ratio is useful for determining
the antibody concentration in a patient or blood do-
nor serum. Thus, antibody titres greater than 16 al-
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ready result in maximal reactivity of the first-gener-
ation enzyme immunoassay, so that EIA I allows no
differentiation of antibody concentrations beyond this
titre (fig. 4). In the second-generation EIA, this sat-
uration response does not occur until a titre greater
than 64 is reached, so that EIA II is somewhat more
amenable to determining a quantitative result from
the absorbance of the undiluted sample.
In summary, it can be said that blood donor sera
contain many sources of false positive reactions, in-
cluding antibodies to yeasts (21), antibodies to the
Superoxide dismutase moiety of the fusion protein
(25), and other cross-reacting antibodies (26, 27).
These reactions are, for obvious reasons, relatively
less frequent in populations at high risk of hepatitis
C infection, such as haemophiliacs and liver disease
patients. The significantly enhanced specificity of EIA
II is presumably the result of using more highly pur-
ified recombinant proteins, as well as of the addition
of the Superoxide dismutase moiety of the fusion
protein, along with E. coli and yeast lysate to sample
diluents.
The enhanced sensitivity of EIA II would, however,
appear to be even more important for blood donor
screening than the improvement in specificity, since
the EIA would then be capable of detecting and
eliminating potentially infectious blood units that
would otherwise be transfused. Several studies have
demonstrated that specific detection of anti-hepatitis
C virus antibodies (14, 23) is associated with infec-
tiousness of the blood, i. e. the antibodies are indica-
tive of chronic viral replication rather than of im-
munity. Disappearance of previously detected anti-
hepatitis C virus antibodies can be considered as
evidence that the disease has healed and/or that viral
replication has been interrupted (28, 29).
The approach of choice for evaluating the safety of
blood products and the patient's infectious status and
prognosis therefore consists of the use of a diagnostic
method that is capable of detecting different anti-
hepatitis C virus antibody specificities with maximum
sensitivity and maximum specificity. The second-gen-
eration anti-hepatitis C virus antibody enzyme im-
munoassay, which uses three distinct recombinant
hepatitis C virus proteins and has been studied in this
investigation, constitutes a significant advance in this
respect. Nevertheless sera that are reactive in this EIA
II should be confirmed by a defined (fully synthetic
and/or recombinant) hepatitis C virus peptide EIA
and/or a multiantigen immunoblot assay (14).
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